# US 2014/0106337 A1 · Methods, nucleic acids, and kits for detection of parvovirus b19

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0106337 A1
- Document ID: US20140106337A1
- Status: Published application
- Kind: A1
- Application number: 14/053,245
- Filed: 2013-10-14
- Published: 2014-04-17
- Earliest claimed: 2007-01-16
- Assignees: Grifols Therapeutics Inc.
- Applicants: Grifols Therapeutics Inc.
- Inventors: DOUGLAS C. LEE; TODD M. GIERMAN; CHRIS GLENN; BURTON BEAMS; BRETT BUNO; LORI RINCKEL
- Web page: https://patentgrep.com/patent/US20140106337A1

## CPC

- C12Q 1/701: {Specific hybridization probes}
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 2750/14221: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Nucleic acid molecules derived from sequences of novel human parvovirus B19 variant genomes are provided. Also provided are assays and kits comprising the nucleic acid molecules.

## Claims

### Claim at position 1

1-18. (canceled)

### Claim 19

An isolated nucleic acid molecule comprising the sequence set forth in:
5′-CACAGCTACAGATGCAAA-3′ (SEQ ID NO:145) or the sequence fully complementary thereto;
5′-GGTGCACACGGCTTTT-3′ (SEQ ID NO:146) or the sequence fully complementary thereto;
5′-TGTCCACAATTCTTCAGGCTTTTCATATCC-3′ (SEQ ID NO:147) or the sequence fully complementary thereto;
5′-TGGATATGAAAAGCCTGAAGTATTGTGGAC-3′ (SEQ ID NO:148) or the sequence fully complementary thereto;
5′-GGTCATTTACCATATGTACT-3′ (SEQ ID NO:149) or the sequence fully complementary thereto;
5′-AGCTACAGATGCAAANCAACACCACAGACA-3′ (SEQ ID NO:150) or the sequence fully complementary thereto;
5′-GAAAACTTTCCATTTAATGATGT-3′ (SEQ ID NO:151) or the sequence fully complementary thereto;
5′-ATTTTTTGATCTACCCTGGT-3′ (SEQ ID NO:152) or the sequence fully complementary thereto;
5′-TTGGTGGTCTGGGATGAAGG-3′ (SEQ ID NO:153) or the sequence fully complementary thereto;
5′-GTTTTATGGGCCGCCAAGTA-3′ (SEQ ID NO:154) or the sequence fully complementary thereto;
5′-TTCATCCCAGACCACCAAGG-3′ (SEQ ID NO:155) or the sequence fully complementary thereto;
5′-ATGGCTATTGCTAAAACTGTTCCAGTGTA-3′ (SEQ ID NO:156) or the sequence fully complementary thereto;
5′-TGGAATAATGAAAACTTTCCATTTAATGATGTAG-3′ (SEQ ID NO:157) or the sequence fully complementary thereto;
or
5′-CAATGGCCATTGCTAAAAGTGTTCCA-3′ (SEQ ID NO:158) or the sequence fully complementary thereto.

### Claim 20

A method for detecting a parvovirus B19 nucleic acid in a sample, the method comprising:
a) performing PCR with at least a portion of the sample using a forward primer having a forward primer nucleic acid sequence and a reverse primer having a reverse primer nucleic acid sequence,
wherein the forward primer nucleic acid sequence is set forth in (SEQ ID NO:145), (SEQ ID NO:149), (SEQ ID NO:151), or (SEQ ID NO:154), and
wherein the reverse primer nucleic acid sequence is set forth in (SEQ ID NO:146), (SEQ ID NO:152), or (SEQ ID NO:155); and
b) determining the presence or absence of an amplicon, wherein the presence of the amplicon is indicative of the presence of the parvovirus B19 nucleic acid in the sample, wherein determining comprises annealing an oligonucleotide to the amplicon.

### Claim 21 (depends on 20)

The method of claim 20, wherein the oligonucleotide comprises the sequence set forth in:
(SEQ ID NO:147) or the sequence fully complementary thereto;
(SEQ ID NO:148) or the sequence fully complementary thereto;
(SEQ ID NO:150) or the sequence fully complementary thereto;
(SEQ ID NO:153) or the sequence fully complementary thereto;
(SEQ ID NO:156) or the sequence fully complementary thereto;
(SEQ ID NO:157) or the sequence fully complementary thereto; or
(SEQ ID NO:158) or the sequence fully complementary thereto.

### Claim 22 (depends on 19)

A kit comprising the isolated nucleic acid molecule of claim 19.